| pubmed-article:1515715 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0006826 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0031001 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0684224 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0023884 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0205054 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0205409 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0522523 | lld:lifeskim |
| pubmed-article:1515715 | lifeskim:mentions | umls-concept:C0439611 | lld:lifeskim |
| pubmed-article:1515715 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:1515715 | pubmed:dateCreated | 1992-10-8 | lld:pubmed |
| pubmed-article:1515715 | pubmed:abstractText | Chemotherapy for primary or metastatic hepatic malignancy is limited by poor tumor response and dose-related systemic toxicity. As an alternative to chemotherapy infusion by vein or by the hepatic artery, the authors have developed a percutaneous technique of isolated liver perfusion that allows the regional delivery of high-dose chemotherapy to the liver with little systemic toxicity. After placement of a hepatic artery infusion catheter, an 18-F double-balloon catheter is placed into the inferior vena cava through the opposite femoral vein. Balloons are inflated above and below the hepatic veins, thus isolating hepatic venous outflow. The effluent passes through fenestrations in the catheter and is pumped through charcoal hemoperfusion filters where the drug is removed. The filtered blood is returned to the patient through the internal jugular vein. Fifteen treatments have been conducted in eight patients in a phase I dose-escalation study with use of 5-fluorouracil (5-FU). While it is premature to assess tumor response to isolated liver perfusion, the data demonstrate that the procedure is safe and is tolerated by patients. Pharmacokinetic studies show a 5-FU extraction of up to 85%, with minimal drug leakage into the systemic circulation. This technique shows potential for improving liver tumor response while decreasing systemic toxicity. | lld:pubmed |
| pubmed-article:1515715 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1515715 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1515715 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1515715 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1515715 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1515715 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:1515715 | pubmed:issn | 1051-0443 | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:MarshJ CJC | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:GlickmanM GMG | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:StrairRR | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:RavikumarT... | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:DennyD FDFJr | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:BoddenWW | lld:pubmed |
| pubmed-article:1515715 | pubmed:author | pubmed-author:BeheshtiM VMV | lld:pubmed |
| pubmed-article:1515715 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1515715 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:1515715 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1515715 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1515715 | pubmed:pagination | 453-8 | lld:pubmed |
| pubmed-article:1515715 | pubmed:dateRevised | 2005-11-17 | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:meshHeading | pubmed-meshheading:1515715-... | lld:pubmed |
| pubmed-article:1515715 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1515715 | pubmed:articleTitle | Percutaneous isolated liver perfusion for treatment of hepatic malignancy: preliminary report. | lld:pubmed |
| pubmed-article:1515715 | pubmed:affiliation | Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Conn. | lld:pubmed |
| pubmed-article:1515715 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1515715 | pubmed:publicationType | Clinical Trial | lld:pubmed |
